HDAC9 and neoplasm: Considering the low efficacy of butyrate compared to that of the new generation of HDAC inhibitors that have had an impact on epigenetic tumor-targeted therapy [23], we focused on butyrate organotin conjugates to improve its efficacy and to understand whether it maintains its epigenetic properties in colon cancer cells.